Immunic Stock Forum

$Immunic (IMUX.US)$ 😎👀

$Immunic (IMUX.US)$ 👀

$Immunic (IMUX.US)$ So been on a tiny, low volume uptrend since a Big Ole Bottom ( Likes me some BOB’s 🤭Hehehe ) on 4/9/25! Also was going through my notes earlier this morning and came across this lil reminder GEM in said notes ((((.     A key upcoming milestone for Immunic is the phase two CALLIPER trial readout, expected in April. The trial is focused on progressive MS, and if results confirm the drug’s neuroprotective effects, it could be the first disease-modifying trea...

$Immunic (IMUX.US)$
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
Wednesday, 26th February at 6:30 am
– Vidofludimus Calcium's Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activations in Preclinical Models –
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April –
NEW YORK, Feb. 26, 2025 /PRNewswi...

$Immunic (IMUX.US)$
Can Immunic's MS Drug Protect Neurons? New Data Reveals Promising Mechanism Ahead of Critical Trial Results

$Immunic (IMUX.US)$
Oral GLP-1 Breakthrough? New Drug Shows 250% Increase in Weight Loss Hormone

$Immunic (IMUX.US)$ Reuters· 3 mins ago
Immunic's Oral Imu-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

$Immunic (IMUX.US)$
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
NEWS PROVIDED BY
Feb 20, 2025, 07:30 ET
Immunic, Inc. Logo (PRNewsfoto/Immunic, Inc.)
– New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready –
– Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Post Hoc Analysis of Patients From Phase 1b Clinica...

$Immunic (IMUX.US)$
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Tuesday, 7th January at 6:30 am
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April –
– Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 –
– Strengthened Management Team and Board of Directors with Key Hir...

$Immunic (IMUX.US)$ https://www.sec.gov/edgar/search/#/ciks=0001280776&entityName=IMMUNIC%252C%2520INC.%2520(IMUX)%2520(CIK%25200001280776)
Anything Important?